Sign In
 [New User? Sign Up]
Mobile Version

Sr Dir Pipeline Team Lead, I&I PHI

Pfizer


Location:
New York, NY
Date:
11/16/2017
2017-11-162017-12-17
Pfizer
Apply on the Company Site
  •  
  • Save Ad
  • Email Friend
  • Print
  • Research Salary

Job Details

To shape the strategic goals of the Inflammation & Immunology (I&I) Business Unit (BU) by overseeing the development of all pipeline assets in Phase 1 through Pivotal Trial study start (Phase 2B or Phase 3). This role directly impacts the ability to achieve business objectives on a global basis by providing strategic guidance on access, pricing, patient value and payer evidence; it is responsible to generate payer insights and develops robust evidence relevant to achieve optimal decision making during proof of concept and dose-finding lifecycles.







This Senior Director (TBC) will function with a One PHI mindset and will lead a team of outcomes scientists and access strategists. She/he will join the PHI I&I LT to ensure there is a single and coordinated view on strategy and delivery for PHI to the I&I business and will collaborate seamlessly with the PHI Centers of Excellence such as RWDnA, PCOA, and others. This Senior Director (TBC) will become a strategic partner to I&I Commercial Development, the I&I Research Unit, I&I Global Product Development as well as Regulatory to develop and implement health outcomes research and market access strategies to support developing assets.







+ Lead Team: Lead the I&I PHI pipeline and development team comprised of outcomes scientists and access strategists.



+ Strategic Partnership: Become an active member of the PHI I&I LT and a strategic partner to business/R&D colleagues



+ Plan & Deliver on Commitments: Lead the execution of outcomes and access studies and projects (including EJP models, payer, pricing research, all components of the VEST - value evidence suite of tools, etc.) in alignment with cross-functional colleagues to demonstrate the value proposition for assets in the I&I pipeline and support critical go/no-go pivotal trial decision making (Phase 2B conditional approval or Phase 3 in PSI). In particular:



+ Incorporate humanistic and economic endpoints into clinical trials across all phases of product development to build comprehensive trial-based evidence in line with overall strategy for the assets and to ensure global reimbursement and access requirements. Provide strategic input in the selection of relevant patient population and comparators within clinical trials to enable successful negotiations, reimbursement, and appropriate patient access with global payer and regulatory decision makers.



+ Development and validation of new Patient Reported Outcomes measures as appropriate for inclusion across clinical trials, registries, and prospective real world studies.



+ Generate payer insights in global markets through early payer advice, EMA/HTA parallel scientific advice, market research, etc. to inform pricing and access strategies and commercial assessments for various product



+ External Partnerships: Develop strategic partnerships and research collaborations with key external experts, healthcare policy makers, payers, patient advocacy groups and various academic and community settings to support asset strategies.







**Qualifications**



Minimum Masters degree (MSc, MPH) in health services research, public health, epidemiology, or health economics with a preferred Doctoral degree (PhD, DrPH, ScD) in health services research, public health, epidemiology, or health economics.



Minimum 10 years' experience in health outcomes/market access and related fields, 5 of which are as part of global health economics and/or outcomes research teams in a pharmaceutical company.



Experienced in leading a team



Strong working knowledge of the technical and methodological aspects of registries and observational study design and implementation. Capable of independently managing complex registry and non-interventional study projects.



Strong methodological skills (study design, data analysis and interpretation) in clinical trials, epidemiology, or health services research is required



In depth understanding of Pharmacoeconomics, Health-related Quality of Life and/or pricing and access dynamics



Knowledge and experience in the I&I therapeutic area is preferred



Experience with HTA organizations such as NICE, SMC, PBAC is desirable



Excellent interpersonal skills required: ability to understand and respond to multiple internal and external customers; build strategic partnerships internally and externally



Excellent oral and written English communication skills required



Strong project management abilities (contracting, budgeting, vendor management) essential. Demonstrated ability to manage multiple projects (multitask) involving complex processes, significant budget, competing deadlines and rapidly shifting priorities



Ability to influence key members of scientific and commercial teams constructively and without conflict



Skilled in functioning within a matrix organization where managing through influence is required



Ability to travel internationally



Three direct reports (outcomes scientists and access strategists)



Matrixed strategic partnership and project leadership required



EEO & Employment Eligibility



Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.







Sunshine Act



Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider's name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the goveAdditional Offer Details:







- Eligible for Relocation Package YES



- Eligible for Employee Referral Bonus Yes







If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.







Pfizer is an equal opportunity employer and complies with all applicable equal employment opportunity legislation in each jurisdiction in which it operates.
Apply on the Company Site
Powered ByLogo

Featured Jobs[ View All ]

Featured Employers [ View All ]